Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Tue Aug 9, 2022

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million Globe Newswire - Mon Aug 8, 2022

- Transaction Supports Progression of CLS-AX Clinical Program -...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022 Globe Newswire - Wed Aug 3, 2022

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022 Globe Newswire - Wed Jul 27, 2022

ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients Globe Newswire - Tue Jul 26, 2022

- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings Globe Newswire - Thu Jul 7, 2022

- Multiple Podium and Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - ALPHARETTA, Ga., July 07, 2022 (GLOBE...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer Globe Newswire - Tue Jun 14, 2022

- Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple Late-Stage Programs to Product...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference Globe Newswire - Wed Jun 8, 2022

ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Wed May 11, 2022

- First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase...

CLSD : 1.2900 (-0.77%)
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology Globe Newswire - Thu May 5, 2022

- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - - Dr. Thomas Ciulla to Participate in a Panel...

CLSD : 1.2900 (-0.77%)

Barchart Exclusives

Natural Gas- Will European Prices Impact U.S. Prices During the Peak Season? Barchart - 17 minutes ago
Natural gas prices are moving into the peak demand season at low levels. After reaching record highs in Europe in 2022 and probing around the $10 level in the U.S., prices have declined to levels where the downside could be limited. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot